US Equity Strategy

Rates spike and equities: what's next?

Equity Strategy

Americas

Keith Parker
Strategist
keith.parker@ubs.com
+1-212-713 3296

Sean Simonds
Strategist
sean.simonds@ubs.com
+1-212-713 2851

Jack Fu
Strategist
jack.fu@ubs.com
+1-212-713 2594

P/E derating has been large amid surge in 10yr

As the US 10yr yield has risen ~100bp YTD, with a ~50bp spike in the last month, the S&P 500 NTM P/E has fallen 17% since Nov. The P/E derating is nearing recession/ slowdown levels of 20%+ and is in line with the 1994 Fed cycle derating. While there have been many drivers of the 10yr rise, the shift from expectations of Fed cuts last fall to now pricing more Fed hikes has likely been the main driver, with 1y1y rates up ~180bp since Nov-Dec. SPX has rallied 10% on avg in the year following a rates spike with much stronger 18% avg rallies when the Fed did not raise rates >1pp within a year. Inflation expectations have been elevated but contained, which makes a benign Fed hike path and further SPX upside likely assuming no breakout in inflation/employment.

SPX path likely driven by Fed path post historic 10y yield spike

The US 10yr has surged to 5.2%, over 80bp above the 1yr moving average and a z-score of 1.6. The 10yr has cleared +1.5 stdev above its 1yr moving average only seven times in 40 years. Many catalysts will affect the path of rates (oil, employment, inflation prints, midterms), but 10y yields did not meaningfully decline for 2+ months post this stage of10yr spikes, and yields increased further in full Fed hiking cycles.

- **Fed hikes moderate -> equities rallied**. When the Fed hiked <100bp within a year of rate spikes in the 2013, 2016, 2021 and 2023 episodes, the 10yr yield settled at elevated levels for ~2mo on avg before falling. After treading water those ~2mo, SPX rallied ~10% on avg the next 6mo and 18% the next year.
- **Fed hiking cycles -> equities weak**. When the Fed hiked by 100+bp within a year of the 10y surge in 1994, 1999 and 2022, SPX returns were negative or flat over the following year. The 10y also took 100 trading days on avg to reach the peak after crossing the +1 stdev threshold (vs 43 for other cases), and took much longer to get back to the moving average (288 days versus 197).

Equities have greater asymmetry to fall in rates, vs downside from higher rates

SPX forward sales growth expectations and CFROI have also increased 2-3pp since Nov, pushing the implied SPX P/E >24x vs ~20x currently, even with the surge in rates (link). The beta of SPX P/E to forward sales growth CAGR is nearly 2x that of bond yields. Our baseline is that valuations+returns remain well supported amid strong EPS growth, with notable upside if higher growth and/or lower rates do get priced. From a fundamental perspective, the rate sensitive part of the economy, housing and investment ex Tech, remains weak. While the jump in rates will be a headwind to activity, it should be less of a headwind than prior rate spikes when investment was strong. A fall in rates would be a much needed tailwind to investment ex Tech.

Strategy: position for period of elevated rates, and asymmetry to lower rates

For a 2mo period of elevated but stabilizing rates, we highlight our High Growth+CFROI at a Discount basket while our High Leverage basket faces headwinds (link). We also see rising odds of a correlated rally into year end if rates pressures abate and earnings beat, making OTM SPX calls attractive. Comparing our Composite REVS scores to rates betas, top ranking subindustries Semis, Pharma, Refining and Div Banks remain attractive and appear less exposed to rates, in our view. We like pairing positive REVS subindustries with higher rates betas against low scoring rate sensitive industries:

- **High REVS and negative rates beta:** Biotech, Building Products, Consumer Finance, Trading Companies & Distributors, Hotels & Leisure and Regional Banks. Homebuilders have the highest rates beta and neutral REVS, though Building Products offers housing exposure, but scores well ahead on fundamentals.

This report has been prepared by UBS Securities LLC. **ANALYST CERTIFICATION AND REQUIRED DISCLOSURES, INCLUDING INFORMATION ON THE QUANTITATIVE RESEARCH REVIEW PUBLISHED BY UBS, BEGIN ON PAGE 12.**

- **Low REVS with negative rates beta:** Renewables, Automobiles, Construction Materials and Healthcare Facilities, alongside Auto Retail, Restaurants, Media and Application Software.

After 10y jump, SPX path likely driven by Fed path


There are eight events since 1985 where the 10yr has increased by more than 1.5.stddev above the 1yr moving average, including now. Peak z-scores across the completed set range from 1.64 (2016) to 3.14 (2022). The key driver of what happens next is whether the Fed enters a full hiking cycle or adjusts rates moderately in our view. Three of the seven completed episodes began inside a Fed hiking cycle where the Fed rate increased by over 1pp within 1yr of the 10yr breakout (1994, 1999, 2022). The other four did not see larger Fed hikes (2013, 2016, 2021, 2023) .

The 10yr has jumped 1.5 standard deviations above its 1-year average only eight times since 1985, including the current episode.

Across all seven completed episodes, the S&P's average forward return from the +1 stdev crossing is roughly flat over the next 3mo (-1.2% at 3 months) before turning higher over 6–12 months (+4.9% 6mo, +10.0% 12mo). In hiking-cycle episodes, equities have historically been down 2.3% after 1 month and down 4.1% after three months. In the other instances, the S&P has been modestly positive over the first month and quarter, then compounding to +10.4% at six months and +17.7% at twelve. There was a ~18pp difference in performance depending on whether the magnitude of Fed rate increases over the next year.

In non/moderate hiking episodes, the S&P was positive at every horizon, modestly so early (+1.4% at one month, +1.0% at three) before compounding to +10.4% at six months and +17.7% at twelve.

Figure 1: US 10yr deviation from 1yr moving average for past rate spikes (in pp)




Source: Bloomberg, UBS

The 10yr is now over 80bp above the 1yr moving average, which is near the average of past rate spike episodes since the 1980s. History suggests rates are likely to stay elevated for at least 2-3mo.

In instances when the Fed hiked rates by >1pp within a year, the 10yr kept rising on avg, and took over 2x longer to reach the eventual peak compared to cases when the Fed path was more benign (102 vs 43 trading days).

~88bp of Fed hikes priced for the next year post the recent hike is borderline but more likely implies the benign path for rates vs what played out in larger hiking cycles.

Figure 2: S&P 500 performance around 10yr spikes



Source: Bloomberg, UBS


Across all seven precedents the S&P averaged –0.2% at one month, –1.2% at three, +4.9% at six and +10.0% at 1yr. Six of seven episodes were positive at both six and twelve months.

In non-hiking/benign episodes, SPX was positive at every horizon, modestly so early (+1.4% at one month, +1.0% at three) before compounding to +10.4% at six months and +17.7% at twelve

In hiking-cycle episodes, the S&P was negative at every horizon: –2.3% at one month, –4.1% at three, –2.5% at six and –0.2% at t the three recovere

P/E de-rating has been large amid rise in rates

Figure 3: SPX forward P/E historical de-ratings




Source: FactSet, UBS

The S&P 500 P/E has fallen by 17% since the fall peaks, which is in line with the de-rating in 1994 during that Fed hiking cycle.

P/E de-ratings around recessions have been 20-30%, so the current multiple decline has already been large.

Fed path key to equity market trajectory

Figure 4: Fed rate increases around past 10yr yield spikes



Source: Bloomberg, UBS

There have been 7 instances of the US 10yr spiking 1.5stdev above the 1yr moving avg. Three instances saw the Fed hike rates by over 100bp within a year - 2022, 1999 and 1994. The other four instances saw no hikes (late 2023, 2021, 2013) or less than 100bp of hikes (2016-17).

With inflation expectations largely in check, particularly if oil stops rising/ falls, we see lower odds of a larger and longer Fed hiking cycle, which is reflected in market pricing. Thus, further rates pressure needs to come from more Fed hikes priced and/or higher inflation expectations - something to closely monitor.


Figure 5: Event analysis where US 10yr yields reach +1.5 stdev above 1yr MA

			S&P 500 Returns from +1 stddev date				10yr yield chg from +1 stddev date (bp)				Event # of days		
z=+1 date	z=+1.5 date	Peak date	1mo	3mo	6mo	12mo	1mo	3mo	6mo	12mo	MA to 1 Stddev	1 Stddev to peak	Peak to MA
02/24/1994	03/21/1994	05/09/1994	-0.8%	-2.4%	0.2%	3.7%	39	77	40	-30	15	53	209
05/07/1999	06/09/1999	08/10/1999	-0.8%	-1.7%	1.3%	6.7%	24	34	10	-60	18	68	169
06/10/2013	06/21/2013	09/05/2013	-0.1%	-0.2%	9.9%	15.7%	35	41	4	-60	26	65	170
11/14/2016	12/14/2016	12/15/2016	5.0%	6.0%	10.9%	19.3%	20	-2	-15	-40	5	23	172
02/12/2021	02/25/2021	03/19/2021	0.2%	5.5%	12.6%	10.0%	37	20	-39	-13	51	26	97
02/08/2022	03/21/2022	10/20/2022	-5.4%	-8.3%	-8.9%	-11.1%	-4	88	3	-5	35	184	112
08/03/2023	09/27/2023	10/19/2023	0.3%	-7.4%	8.1%	25.9%	-8	53	-34	-68	58	56	40
09/01/2026	09/23/2026												
		Median	-0.1%	-1.7%	8.1%	10.0%	24	41	3	-40	26	56	169
		Average	-0.2%	-1.2%	4.9%	10.0%	20	44	-4	-39	30	68	138

Source: Bloomberg, UBS

10yr breakout driven by real yields, not inflation


Figure 6: US 10yr nominal yield vs 1yr moving average



Source: Bloomberg, UBS

The US 10yr yield recently broke out of the trailing 3-year range and reached 5.2% vs a 1-year moving average of 4.4%, an ~0.8pp gap.


Figure 7: US 10yr nominal yield difference vs 1yr moving average



Source: Bloomberg, UBS

The US 10yr deviation from its 1yr moving average is a z-score of +1.64 and in the 93rd percentile vs history, putting it in rare company of 7 events since the 1980s that reached a >1.5 stddev.

Figure 8: US 10yr inflation breakeven vs 1yr moving average




Source: Bloomberg, UBS

Inflation breakevens are in line with the moving avg (+0.01pp), noting that inflation expectations have not driven the increase in rates unlike other periods.

US 10yr and SPX around past rate spikes


Figure 9: US 10yr yield around past rate spikes (deviation from MA in pp)



Source: Bloomberg, UBS

The US 10yr is up about 100bp YTD with ~50bp of the jump in the last month. The path of the 10yr following breakouts 1.5stdev above average has varied greatly with 2022 and 1994 seeing even higher 10yr rates amid Fed hiking cycles post recessions. Other instances saw the 10yr settle down at this stage.

Figure 10: S&P 500 performance around past 10yr yield spikes



Source: Bloomberg, UBS

The path for equities has largely depended on the path for Fed hikes post rate spikes.

A more benign Fed hike path and settling down of short rate expectations would pave the way for strong earnings and growth to drive further equity upside post the large P/E derating.

Valuations pricing higher rates and/or lower growth/margins


Valuations have fallen over the last 6-9mo as earnings have surged, profitability has improved and forward growth expectations have been revised up. Markets appear to be pricing slower growth, lower margins and/or higher rates. Given accelerating growth in many areas, the de-rating has been "early" and larger compared to past cycles, but discounting through cycle earnings/margins is a continued challenge.

With the SPX P/E to sales growth CAGR near 2008-12 lows, earnings should fuel further upside with valuations generally well supported.

There are many drivers of equity valuations but they can essentially be grouped into: 1) bond yields, 2) cyclical growth, 3) secular/terminal growth, 4) quality/uncertainty, 5) return of capital. Our forward sales growth CAGR is the most significant variable in the SPX valuation framework, on a univariate basis, while CFROI is the most significant variable in the broad P/E framework. The rise in fwd sales CAGR and CFROI has pushed the implied SPX P/E to >24x based on our framework. With ~21% upside to the implied P/E, the residual is at levels seen in 2020 and 2011-12. Our baseline is that valuations remain well supported amid strong EPS growth, with large upside if higher growth does get priced.


Leveraging our prior work, we develop a new SPX P/E framework incorporating more fundamental variables to account for the changes in growth and profitability for the S&P 500, in addition to macro variables.

Figure 11: Bond yields point to a lower P/E...




Source: Bloomberg, UBS

Figure 12: ...but higher sales growth supports a higher P/E



Source: Bloomberg, UBS. Note: Sales CAGR is avg of float and fundamental wtd.

Figure 13: S&P 500 NTM P/E is below our model implied value




Variable	Beta	t-stat	Current level	Contribution
US 10yr + IG OAS	-1.19	34.5	5.5	-6.5
Economic surprises	0.89	7.8	0.1	0.1
US 1yr minus Fed rate	-0.04	0.7	0.4	0.0
Sales growth - 3-5yr CAGR	1.48	20.8	3.6	5.4
Cash flow ROI	0.76	26.8	8.1	6.1
Equity vol / rates vol	-4.80	9.6	0.2	-1.0
Sales growth inflection	0.19	10.4	-1.9	-0.4
Dividend payout	0.11	11.3	21.8	2.4
Intercept				18.5
Implied P/E				**24.5**

Source: FactSet, Bloomberg, UBS

Sensitivity of growth to rates should be lower

Figure 14: US real non-residential investment vs US real investment ex IT equip & IPP (y/y%)



Source: BEA, Haver, UBS

US real investment outside of Tech has been weak for years after the Fed hiked rates in 2022-23 with further declines over the last year-plus. While higher rates will be a headwind for growth activity, the beta of rate sensitive investment to higher rates should be lower given weak levels of activity currently.

Figure 15: New and existing home sales are already at very weak levels



Source: Bloomberg, UBS

In particular, housing activity is most sensitive to higher bond yields. But existing home sales are running at GFC levels already, while new home sales have also dipped and remain weak.

Subindustry rate sensitivity vs fundamental attractiveness


Not every rate-sensitive business is equally worth owning amid rates uncertainty. To better assess the relative strategy setup, we leverage our Composite REVS scores at the subindustry level against the beta to change in rates, separating groups where duration exposure is backed by improving fundamentals from those where a lower 10yr may be the only catalyst.

Top scoring subindustries that are rates neutral include Refining, Semis, Diversified Banks, Diversified Financial Services, Construction Machinery and Pharmaceuticals as they all carry a low beta to rates in our analysis. Owning the best fundamental momentum does not require taking a duration view.

Higher scoring fundamentals with negative rates beta can pair duration exposure with fundamental momentum. Consumer Finance, Trading Companies & Distributors, Biotech, Building Products, Hotels & Leisure and Regional Banks all rank in the top quartile of the composite REVS while screening negative to rates. Building Products in particular offers the housing exposure that Homebuilding does, but with fundamental momentum 38 places higher.

Negative REVS industries with higher rate sensitivity can be a source of funds and includes subindustries such as Renewables, which screens among the worst on REVS and carries a negative rates beta. Automobiles, Construction Materials and Healthcare Facilities are next among worst scoring subindustries with high rates betas. Auto Retail, Restaurants, Other Retail, Healthcare Equipment, Media and Application Software are in the same quadrant.


Figure 16: Subindustry REVS composite scores vs beta to interest rates



Source: UBS

S&P 500 stock valuations have 'normalized' since Jan as EPS has risen well above trend


Figure 17: Distribution of Valuations in the S&P 500 have normalized significantly



Source: FactSet, UBS

The average NTM P/E of 19.4x and median of 16.6x are in line with historical averages, while the typical stock trades at only the 40th percentile of its own history. Both measures have fallen meaningfully since January.

Figure 18: SPX earnings are now well above trend



Source: FactSet, UBS. Note: EPS in log term

The SPX LTM P/E had a beta of -0.12 to the % difference between EPS and the historical trend based on our trailing P/E model (link).

The 1yr jump in EPS well above trend would have pointed to a ~3x de-rating, all else equal.

However, expected sales growth and CFROI are a lot higher which would support a higher multiple.

Valuation Method and Risk Statement

Equity market returns are influenced by corporate earnings, interest rates, risk premia, as well as other variables influenced by the business cycle. The outlook for any and all of these variables is subject to change.
Risks include macroeconomic variables (such as GDP growth rates and inflation), economic slowdown, a weakening currency, global economic events, and government policy changes. Our quantitative models rely on reported financial statement information, consensus earnings forecasts and stock prices. Errors in these numbers are sometimes impossible to prevent (as when an item is misstated by a company). Also, the models employ historical data to estimate the efficacy of stock selection strategies and the relationships among strategies, which may change in the future. Additionally, unusual company-specific events could overwhelm the systematic influence of the strategies used to rank and score stocks. Past performance is not a guarantee of future performance. Valuation methods across sectors include DCF, SOTP and multiples analysis.
Options, structured derivative products and futures (including OTC derivatives) are not suitable for all investors. Trading in these instruments is considered risky and may be appropriate only for sophisticated investors. Prior to buying or selling an option, and for the complete risks relating to options, you must receive a copy of "The Characteristics and Risks of Standardized Options." You may read the document at http://www.theocc.com/publications/risks/riskchap1.jsp or ask your salesperson for a copy. Various theoretical explanations of the risks associated with these instruments have been published. Supporting documentation for any claims, comparisons, recommendations, statistics or other technical data will be supplied upon request. Past performance is not necessarily indicative of future results. Transaction costs may be significant in option strategies calling for multiple purchases and sales of options, such as spreads and straddles. Because of the importance of tax considerations to many options transactions, the investor considering options should consult with his/her tax advisor as to how taxes affect the outcome of contemplated options transactions. All options discussed in this report are OTC options.

Required Disclosures

This document has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates, including former Credit Suisse AG and its subsidiaries, branches and affiliates are referred to herein as "UBS".

For information on the ways in which UBS manages conflicts and maintains independence of its UBS Global Research product; historical performance information; certain additional disclosures concerning UBS Global Research recommendations; and terms and conditions for certain third party data used in research report, please visit https://www.ubs.com/disclosures. Unless otherwise indicated, information and data in this report are based on company disclosures including but not limited to annual, interim, quarterly reports and other company announcements. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. This recommendation was finalized on: 28 September 2026 01:05 AM GMT. UBS has designated certain UBS Global Research department members as Derivatives Research Analysts where those department members publish research principally on the analysis of the price or market for a derivative, and provide information reasonably sufficient upon which to base a decision to enter into a derivatives transaction. Where Derivatives Research Analysts co-author research reports with Equity Research Analysts or Economists, the Derivatives Research Analyst is responsible for the derivatives investment views, forecasts, and/or recommendations. **Quantitative Research Review:** UBS Global Research publishes a quantitative assessment of its analysts' responses to certain questions about the likelihood of an occurrence of a number of short term factors in a product known as the 'Quantitative Research Review'. Views contained in this assessment on a particular stock reflect only the views on those short term factors which are a different timeframe to the 12-month timeframe reflected in any equity rating set out in this note. For the latest responses, please see the Quantitative Research Review Addendum at the back of this report, where applicable. For previous responses please make reference to (i) previous UBS Global Research reports; and (ii) where no applicable research report was published that month, the Quantitative Research Review which can be found at https://neo.ubs.com/quantitative, or contact your UBS sales representative for access to the report or the Quantitative Research Team on ubs-quant-answers@ubs.com. A consolidated report which contains all responses is also available and again you should contact your UBS sales representative for details and pricing or the Quantitative Research team on the email above.

Analyst Certification:
Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

UBS Global Research: Global Equity Rating Definitions

12-Month Rating	Definition	Coverage[1]	IB Services[2]
Buy	FSR is > 6% above the MRA.	55%	24%
Neutral	FSR is between -6% and 6% of the MRA.	40%	21%
Sell	FSR is > 6% below the MRA.	6%	21%

Source: UBS. Rating allocations are as of 30 June 2026.
1:Percentage of companies under coverage globally within the 12-month rating category.
2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

KEY DEFINITIONS:Forecast Stock Return (FSR) is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months. In some cases, this yield may be based on accrued dividends. **Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium). **Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Equity Price Targets** have an investment horizon of 12 months.

EXCEPTIONS AND SPECIAL CASES:UK and European Investment Fund ratings and definitions are: Buy: Positive on factors such as structure, management, performance record, discount; **Neutral:** Neutral on factors such as structure, management, performance record, discount; **Sell:** Negative on factors such as structure, management, performance record, discount. **Core Banding Exceptions (CBE):** Exceptions to the standard +/-6% bands may be granted by the Investment Review Consultation (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/ qualified as research analysts with FINRA. Such analysts may not be associated persons of UBS Securities LLC and therefore are not subject to the FINRA restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

UBS Securities LLC: Jack Fu, Keith Parker, Sean Simonds.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report. For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, please contact UBS Securities LLC, 11 Madison Avenue, New York, NY 10010, USA, Attention: Investment Research.

UBS Global Research Disclaimer

This document has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates, including former Credit Suisse AG and its subsidiaries, branches and affiliates are referred to herein as "UBS".

Any opinions expressed in this document may change without notice and are only current as of the date of publication. Different areas, groups, and personnel within UBS may produce and distribute separate research products independently of each other. For example, research publications from **UBS CIO** are produced by UBS Global Wealth Management. **UBS Global Research** is produced by UBS Investment Bank. Research methodologies and rating systems of each separate research organization may differ, for example, in terms of investment recommendations, investment horizon, model assumptions, and valuation methods. As a consequence, except for certain economic forecasts (for which UBS CIO and UBS Global Research may collaborate), investment recommendations, ratings, price targets, and valuations provided by each of the separate research organizations may be different, or inconsistent. You should refer to each relevant research product for the details as to their methodologies and rating system. Not all clients may have access to all products from every organization. Each research product is subject to the policies and procedures of the organization that produces it.

This document is provided solely to recipients who are expressly authorized by UBS to receive it. If you are not so authorized you must immediately destroy the document.

UBS Global Research is provided to our clients through UBS Neo, and in certain instances, UBS.com and any other system or distribution method specifically identified in one or more communications distributed through UBS Neo or UBS.com (each a system) as an approved means for distributing UBS Global Research. It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means.

All UBS Global Research is available on UBS Neo. Please contact your UBS sales representative if you wish to discuss your access to UBS Neo. Where UBS Global Research refers to "UBS Evidence Lab Inside" or has made use of data provided by UBS Evidence Lab and you would like to access that data please contact your UBS sales representative. UBS Evidence Lab data is available on UBS Neo. The level and types of services provided by UBS Global Research and UBS Evidence Lab to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g., market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS Global Research and UBS Evidence Lab and legal and regulatory constraints. UBS HOLT and UBS Pharma Values are offerings of UBS Global Research. HOLT Lens is a corporate performance platform offering that provides an objective accounting-led framework for comparing and valuing companies and is available to clients of UBS Global Research; for further details and pricing please contact your UBS Sales representative. In particular, HOLT has a variety of warranted prices based on the scenario chosen; please mail UBS Securities LLC, 11 Madison Avenue, New York, NY 10010, USA, Attention: Investment Research, if you are interested in the warranted price on a particular company, again subject to commercial considerations. UBS Pharma Values is an analytical tool that involves the creation of a number of individual product net present value calculations, based on published forecasts of sales for pharmaceuticals, and is available to clients of UBS Global Research; for further details and pricing please contact your UBS Sales representative. For all other specific disclaimers, please see https://www.ubs.com/disclosures.

When you receive UBS Global Research through a system, your access and/or use of such UBS Global Research is subject to this UBS Global Research Disclaimer and to the UBS Neo Platform Use Agreement (the "Neo Terms") together with any other relevant terms of use governing the applicable System.

When you receive UBS Global Research via a third party vendor, e-mail or other electronic means, you agree that use shall be subject to this UBS Global Research Disclaimer, the Neo Terms and where applicable the UBS Investment Bank terms of business (https://www.ubs.com/global/en/investment-bank/regulatory.html) and to UBS's Terms of Use/Disclaimer (https://www.ubs.com/global/en/legalinfo2/disclaimer.html). In addition, you consent to UBS processing your personal data and using cookies in accordance with our Privacy Statement (https://www.ubs.com/global/en/legalinfo2/privacy.html) and cookie notice (https://www.ubs.com/global/en/legal/privacy/users.html).

If you receive UBS Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, provide to any third party, or in any way commercially exploit any UBS research provided via UBS Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via UBS Global Research or otherwise, without the prior written consent of UBS. You agree not to use UBS Global Research in any artificial intelligence system, without the prior written consent of UBS.

In certain circumstances you may receive UBS Global Research otherwise than in the capacity of a client of UBS and you understand and agree that under these circumstances (i) the UBS Global Research is provided to you for information purposes only; (ii) for the purposes of receiving it you are not intended to be and will not be treated as a "client" of UBS for any legal or regulatory purpose; (iii) the UBS Global Research must not be relied on or acted upon for any purpose; and (iv) such content is subject to the relevant disclaimers that follow.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction.

This document is a general communication and is educational in nature; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. By providing this document, none of UBS or its representatives has any responsibility or authority to provide or have provided investment advice in a fiduciary capacity or otherwise. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. None of UBS or its representatives is suggesting that the recipient or any other person take a specific course of action or any action at all. The recipient should carefully read this document in its entirety and not draw inferences or conclusions from the rating alone. By receiving this document, the recipient acknowledges and agrees with the intended purpose described above and further disclaims any expectation or belief that the information constitutes investment advice to the recipient or otherwise purports to meet the investment objectives of the recipient. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors.

Options, structured derivative products and futures (including OTC derivatives) are not suitable for all investors. Trading in these instruments is considered risky and may be appropriate only for sophisticated investors. Prior to buying or selling an option, and for the complete risks relating to options, you must receive a copy of "The Characteristics and Risks of Standardized Options." You may read the document at https://www.theocc.com/publications/risks/riskchap1.jsp or ask your salesperson for a copy. Various theoretical explanations of the risks associated with these instruments have been published. Supporting documentation for any claims, comparisons, recommendations, statistics or other technical data will be supplied upon request. Past performance is not necessarily indicative of future results. Transaction costs may be significant in option strategies calling for multiple purchases and sales of options, such as spreads and straddles. Because of the importance of tax considerations to many options transactions, the investor considering options should consult with his/her tax advisor as to how taxes affect the outcome of contemplated options transactions.

Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

UBS notes that no globally accepted framework or definition (legal, regulatory or otherwise) currently exists, nor is there a market consensus as to what constitutes an "ESG" (Environmental, Social or Governance) or an equivalent-label, or as to what precise attributes are required for the Information (as defined below) to be defined as ESG or equivalently-labelled. Any information, data or other content including from a third party source contained, referred to herein or used for whatsoever purpose by UBS or a third party ("Information"), in relation to any actual or potential ESG objective, issue or consideration is not intended to be relied upon for ESG classification, regulatory regime or industry initiative purposes ("ESG Regimes"). Nothing in these materials is intended to convey, suggest or indicate that UBS considers or represents any product, service, person or body mentioned in these materials as meeting or qualifying for any ESG classification, labelling or similar standards that may exist under the ESG Regimes. UBS has not conducted any assessment of compliance with ESG Regimes. Parties are reminded to make their own assessments for these purposes.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Prior to making any investment or financial decisions, any recipient of this document or the information should take steps to understand the risk and return of the investment and seek individualized advice from his or her personal financial, legal, tax and other professional advisors that takes into account all the particular facts and circumstances of his or her investment objectives.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in any materials to which this document relates (the "Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the

Information. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. In no circumstances may this document or any of the Information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following purposes:

(i) valuation or accounting purposes;

(ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or

(iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS and among its subsidiaries, branches and affiliates. UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For further information on the ways in which UBS Global Research manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS Global Research recommendations, please visit https://www.ubs.com/disclosures.

UBS Global Research will initiate, update and cease coverage solely at the discretion of UBS Global Research Management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. All material information in relation to published research reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those assumptions), ratings history etc. as required by the Market Abuse Regulation, can be found on UBS Neo. Different assumptions could result in materially different results.

UBS Global Research may utilise artificial intelligence tools ("AI Tools") in the preparation of this document. Notwithstanding any such use of AI Tools, this document has undergone human review.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by UBS Global Research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS and/or its divisions as a whole, of which investment banking, sales and trading are a part, and UBS as a whole.

For financial instruments admitted to trading on an EU regulated market: UBS (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms under English law or, if not carried out by UBS in the UK the law of the relevant jurisdiction in which UBS determines it carries out the activity) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

Within the past 12 months UBS may have received or provided investment services and activities or ancillary services as per MiFID II which may have given rise to a payment or promise of a payment in relation to these services from or to this company.

Please note that all transactions conducted by UBS are consistent with sanctions regulations imposed by Switzerland, the European Union, the United Nations, the United Kingdom and the United States, per UBS' global sanctions policy. UBS opinion as to future investment worthiness assumes no new sanctions are imposed.

US persons are prohibited from purchasing or selling securities of certain companies designated as being associated with the Chinese Military in accordance with the amended US Presidential Executive Order 13959.

United Kingdom: This material is distributed by UBS AG, London Branch to persons who are eligible counterparties or professional clients. UBS AG, London Branch is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. **Europe:** Except as otherwise specified herein, these materials are distributed by UBS Europe SE, a subsidiary of UBS AG, to persons who are eligible counterparties or professional clients (as detailed in the Bundesanstalt fur Finanzdienstleistungsaufsicht (BaFin) Rules and according to MIFID) and are only available to such persons. The information does not apply to, and should not be relied upon by, retail clients. UBS Europe SE is authorised by the European Central Bank (ECB) and regulated by the BaFin and the ECB. **Germany, Luxembourg, the Netherlands, Belgium and Ireland:** Where an analyst of UBS Europe SE has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE. In all cases it is distributed by UBS Europe SE and UBS AG, London Branch. **Turkey:** Distributed by UBS AG, London Branch. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG, London Branch is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. **Poland:** Distributed by UBS Europe SE (spolka z ograniczona odpowiedzialnoscia) Oddzial w Polsce. Where an analyst of UBS Europe SE (spolka z ograniczona odpowiedzialnoscia) Oddzial w Polsce has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE (spolka z ograniczona odpowiedzialnoscia) Oddzial w Polsce. **Russia:** Prepared and distributed by UBS Bank (OOO). Should not be construed as an individual Investment Recommendation for the purpose of the Russian Law - Federal Law #39-FZ ON THE SECURITIES MARKET Articles 6.1-6.2.**Switzerland:** Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA). **Italy:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Europe SE, Italy Branch. Where an analyst of UBS Europe SE, Italy Branch has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE, Italy Branch. **France:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Europe SE, France Branch. Where an analyst of UBS Europe SE, France Branch has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE, France Branch. **Spain:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Europe SE, Spain Branch. Where an analyst of UBS Europe SE, Spain Branch has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE, Spain Branch. **Sweden:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Europe SE, Sweden Branch. Where an analyst of UBS Europe SE, Sweden Branch has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE, Sweden Branch. **South Africa:** Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328). **Saudi Arabia:** This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. **UAE / Dubai:** The information distributed by UBS AG Dubai Branch is only intended for Professional Clients and/or Market Counterparties, as classified under the DFSA rulebook. No other person should act upon this material/communication. The information is not for further distribution within the United Arab Emirates. UBS AG Dubai Branch is regulated by the DFSA in the DIFC. UBS is not licensed to provide banking services in the UAE by the Central Bank of the UAE, nor is it licensed by the UAE Securities and Commodities Authority. **Israel:** This Material is distributed by UBS AG, London Branch. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS AG, London Branch and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS AG, London Branch and its affiliates may prefer various Financial Assets to which they have or may have an Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this Material must not be furnished to, relied on or acted upon by any other persons. **United States:** Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a **'non-US affiliate'**) to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a report prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this report must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule. **Canada:** Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from

registration. **Brazil:** Except as otherwise specified herein, this Material is prepared by UBS BB Corretora de Câmbio, Títulos e Valores Mobiliários S.A. (UBS BB CCTVM) to persons who are eligible investors residing in Brazil, which are considered to be Professional Investors (Investidores Profissionais), as designated by the applicable regulation, mainly the CVM Resolution No. 30 from the 11th of May 2021 (determines the duty to verify the suitability of products, services and transactions with regards to the client's profile). UBS BB CCTVM is a subsidiary of UBS BB Servicos de Assessoria Financeira e Participacoes S.A. ("UBS BB"). UBS BB is an association between UBS AG and Banco do Brasil (through its subsidiary BB – Banco de Investimentos S.A.), of which UBS AG is the majority owner and which provides investment banking services and coverage in Brazil, Argentina, Chile, Paraguay, Peru and Uruguay. UBS BB CCTVM is regulated by the Comissao de Valores Mobiliarios (CVM) and by the Central Bank of Brazil. Ombudsman: 0800-940-0266/ https://www.ubs.com/br/pt/ubsbb-investment-bank/ombudsman.html. UBS may hold relevant financial and commercial interest in relation to the company subject to this Research report. **Hong Kong:** Distributed by UBS Securities Asia Limited. Please contact local licensed persons of UBS Securities Asia Limited in respect of any matters arising from, or in connection with, the analysis or document **Singapore:** Distributed by UBS Securities Pte. Ltd. [Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). **Japan:** Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this report has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the report. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant. **Australia:** Recipients through a superannuation fund: Distributed by UBS AG, Australia Branch (ABN 47 088 129 613 and holder of Australian Financial Service Licence No. 231087). For all other recipients: Distributed by UBS Securities Australia Limited (ABN 62 008 586 481 and holder of Australian Financial Services Licence No. 231098). This document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the Information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. **New Zealand:** Distributed by UBS New Zealand Ltd. UBS New Zealand Ltd is not a registered bank in New Zealand. You are being provided with this publication or material because you have indicated to UBS that you are a "wholesale client" within the meaning of clause 4 of schedule 5 of the Financial Markets Conduct Act 2013 of New Zealand (Permitted Client). This publication or material is not intended for clients who are not Permitted Clients (non-permitted Clients). If you are a non-permitted Client you must not rely on this publication or material. If despite this warning you nevertheless rely on this publication or material, you hereby (i) acknowledge that you may not rely on the content of this publication or material and that any recommendations or opinions in such this publication or material are not made or provided to you, and (ii) to the maximum extent permitted by law (a) indemnify UBS and its associates or related entities (and their respective Directors, officers, agents and Advisors) (each a 'Relevant Person') for any loss, damage, liability or claim any of them may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material and (b) waive any rights or remedies you may have against any Relevant Person for (or in respect of) any loss, damage, liability or claim you may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material. **Korea:** Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This report may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. This material is intended for professional/institutional clients only and not for distribution to any retail clients. **Malaysia:** This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMSL/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients. **India:** Distributed by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) Unit 2901, Level 29 Altimus, Pandurang Budhkar Road, Worli, Mumbai – 400 018. It provides brokerage services bearing SEBI Registration Number: INZ000259830; Merchant Banking services bearing SEBI Registration Number: INM000013101; and Research Analyst services bearing SEBI Registration Number: INH000001204. Name of Compliance Officer Mr. Parameshwaran Shivaramakrishnan, Phone : +912261556151, Email : parameshwaran.s@ubs.com, Name of Grievance Officer Parameshwaran Shivaramakrishnan, Phone : +912261556151, Email: ol-ubs-sec-compliance@ubs.com Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. UBS may have debt holdings or positions in the subject Indian company/companies. UBS may have financial interests (e.g. loan/derivative products, rights to or interests in investments, etc.) in the subject Indian company / companies from time to time. Within the past 12 months, UBS may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: https://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html The Research Annual Compliance Report for UBS Securities India Private Limited is available on www.ubs.com/ubssi under Research tab. **Taiwan:** Except as otherwise specified herein, this material may not be distributed in Taiwan. Information and material on securities/instruments that are traded in a Taiwan organized exchange is deemed to be issued and distributed by UBS Securities Pte. LTD., Taipei Branch to professional institutional investors and/or persons permitted under applicable regulation. Unless permitted by applicable Taiwan laws and regulations, this material is for reference and information only and should not constitute "recommendation" to clients or recipients in Taiwan for the covered companies or any companies mentioned in this document. No portion of the document may be reprinted, reproduced or quoted by the press or any other person without authorisation from UBS. **Indonesia:** This report is being distributed by PT UBS Sekuritas Indonesia and is delivered by its licensed employee(s), including marketing/sales person, to its client. PT UBS Sekuritas Indonesia, having its registered office at Sequis Tower Level 22 unit 22-1,Jl.Jend. Sudirman, kav.71, SCBD lot 11B, Jakarta 12190. Indonesia, is a subsidiary company of UBS AG and licensed under Capital Market Law no. 8 year 1995, a holder of broker-dealer and underwriter licenses issued by the Capital Market and Financial Institution Supervisory Agency (now Otoritas Jasa Keuangan/OJK). PT UBS Sekuritas Indonesia is also a member of Indonesia Stock Exchange and supervised by Otoritas Jasa Keuangan (OJK). Neither this report nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens except in compliance with applicable Indonesian capital market laws and regulations. This report is not an offer of securities in Indonesia and may not be distributed within the territory of the Republic of Indonesia or to Indonesian citizens in circumstance which constitutes an offering within the meaning of Indonesian capital market laws and regulations.

The disclosures contained in research documents produced by UBS AG, London Branch or UBS Europe SE shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and in any event UBS accepts no liability whatsoever for any redistribution of this document or its contents or the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2026. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

